Study #2021-1011
Pilot, non-randomized, open-label study of intralesional nivolumab for high risk oral premalignant lesions
MD Anderson Study Status
Enrolling
Treatment Agent
Nivolumab
Description
To characterize the safety and tolerability of nivolumab injected intralesionally in patients with high-risk oral premalignant lesions.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Head and Neck Cancer
Study phase:
Phase I
Physician name:
Moran Amit
Department:
Head & Neck Surgery
For general questions about clinical trials:
1-844-227-7897
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.